Semaglutide vs AOD-9604 & CJC-1295 & Ipamorelin (Stack)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Full details →AOD-9604 & CJC-1295 & Ipamorelin (Stack)
A targeted fat loss stack combining AOD-9604 (the fat-burning fragment of HGH) with CJC-1295 and Ipamorelin for comprehensive body recomposition. This blend addresses fat loss directly while supporting lean mass through GH optimization.
Full details →Side-by-Side Comparison
| Aspect | Semaglutide | AOD-9604 & CJC-1295 & Ipamorelin (Stack) |
|---|---|---|
| Mechanism | Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control. | AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or blood glucose. CJC-1295 and Ipamorelin provide sustained and pulsatile GH release to support metabolism and lean tissue. The combination targets fat loss through multiple mechanisms while preserving muscle. |
| Typical Dosage | Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary. | Typical protocol: AOD-9604 200-400mcg, CJC-1295 100-200mcg, Ipamorelin 100-200mcg daily. Usually administered in the morning fasted or before exercise. |
| Administration | Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects. | Subcutaneous injection. Best administered fasted to maximize fat-burning effects. Can be taken as a pre-mixed blend or separate injections. Cycles typically run 8-16 weeks. |
| Side Effects | Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions. | Mild injection site reactions, headache, nausea. Generally well-tolerated as AOD-9604 lacks many HGH side effects. |
| Best For |
What They Have in Common
Both Semaglutide and AOD-9604 & CJC-1295 & Ipamorelin (Stack) are commonly used for: